Literature DB >> 9307265

Inappropriate retinoic acid receptor-beta expression in oral dysplasias: correlation with acquisition of the immortal phenotype.

F McGregor1, E Wagner, D Felix, D Soutar, K Parkinson, P R Harrison.   

Abstract

Retinoids are useful in the treatment of premalignant oral lesions and in preventing the occurrence of second primary cancers after resection of the initial primary oral cancer, but long-term prognosis is still poor, presumably due to malignant cells escaping retinoid control. Previous work has shown that loss of expression of retinoic acid receptor beta is one of the most consistent molecular changes during oral cancer progression in vivo. In this report we demonstrate, using a novel panel of primary cultures of oral lesions, that loss of retinoic acid receptor beta expression at the dysplasia stage occurs during the transition from senescent to immortal phenotype but may occur independently to the loss of CDKN2A/p16 expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307265

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Tumor-suppressive activity of retinoic acid receptor-beta in cancer.

Authors:  Xiao-Chun Xu
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

2.  Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.

Authors:  Shumei Song; Baoxiang Guan; Taoyan Men; Ashraful Hoque; Reuben Lotan; Xiao-Chun Xu
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-03

3.  Development of tissue-engineered models of oral dysplasia and early invasive oral squamous cell carcinoma.

Authors:  H E Colley; V Hearnden; A V Jones; P H Weinreb; S M Violette; S Macneil; M H Thornhill; C Murdoch
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

4.  Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization.

Authors:  S Y Jiang; S R Shen; R Y Shyu; J C Yu; H J Harn; M Y Yeh; M M Lee; Y C Chang
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma.

Authors:  Lav Darda; Fahad Hakami; Richard Morgan; Craig Murdoch; Daniel W Lambert; Keith D Hunter
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  Methylation-associated gene silencing of RARB in areca carcinogens induced mouse oral squamous cell carcinoma.

Authors:  Zi-Lun Lai; Yung-An Tsou; Shin-Ru Fan; Ming-Hsui Tsai; Hsiao-Ling Chen; Nai-Wen Chang; Ju-Chien Cheng; Chuan-Mu Chen
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

7.  HOPX functions as a tumour suppressor in head and neck cancer.

Authors:  Lee Fah Yap; Sook Ling Lai; Sathya Narayanan Patmanathan; Ravindran Gokulan; C Max Robinson; Joe B White; San Jiun Chai; Pathmanathan Rajadurai; Narayanan Prepageran; Yew Toong Liew; Victor Lopes; Wenbin Wei; Robert J Hollows; Paul G Murray; Daniel W Lambert; Keith D Hunter; Ian C Paterson
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

8.  Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.

Authors:  Anne M van Harten; D Vicky de Boer; Sanne R Martens-de Kemp; Marijke Buijze; Sonja H Ganzevles; Keith D Hunter; C René Leemans; Victor W van Beusechem; Rob M F Wolthuis; Renée X de Menezes; Ruud H Brakenhoff
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.